Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GLS | O94925 | 6/20 | 0.41 |
| ▸ | PPARG | P37231 | 3/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1145682 | 0.85 | L3MBTL1 (0.56) | PTGS1L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL18890289 | 0.85 | L3MBTL1 (0.56) | PTGS1L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL29544093 | 0.85 | L3MBTL1 (0.56) | PTGS1L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL29544040 | 0.85 | L3MBTL1 (0.56) | PTGS1L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL21326187 | 0.85 | L3MBTL1 (0.56) | PTGS1L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL29392091 | 0.85 | GPR139 (0.46) | PTGS1GLSPPARG | |
| SCHEMBL29017154 | 0.85 | GPR139 (0.46) | PTGS1GLSPPARG | |
| SCHEMBL17295978 | 0.85 | GPR139 (0.46) | PTGS1GLSPPARG | |
| Hydrochloric Acid SCHEMBL7051120 | 0.84 | L3MBTL1 (0.55) | PTGS1L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL17295988 | 0.84 | GLS (0.42) | PTGS1L3MBTL1TAS2R14MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108349967-B | 1,3, 4-thiadiazole compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2022-02-15 | — | — | CN | disclosed |
| CN-108349951-B | Bispyridazine compound | 阿斯利康(瑞典)有限公司 | 2020-11-13 | — | — | CN | disclosed |
| EP-3380468-B1 | BIS-PYRIDAZINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2020-05-20 | — | — | EP | disclosed |
| EP-3380468-B1 | BIS-PYRIDAZINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2020-05-20 | — | — | EP | disclosed |
| US-10577354-B2 | Bis-pyridazine compounds and their use in treating cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-03-03 | — | — | US | disclosed |
| US-10577354-B2 | Bis-pyridazine compounds and their use in treating cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-03-03 | — | — | US | disclosed |
| CN-106795150-B | 1,3,4- thiadiazole compound and its purposes in treating cancer | 阿斯利康(瑞典)有限公司 | 2019-10-15 | — | — | CN | disclosed |
| EP-3383871-B1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-09-11 | — | — | EP | disclosed |
| EP-3383871-B1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-09-11 | — | — | EP | disclosed |
| US-20190169172-A1 | bis-Pyridazine Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2019-06-06 | — | — | US | disclosed |
| WO-2017089587-A1 | BIS-PYRIDAZINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089587-A1 | BIS-PYRIDAZINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-06-01 | — | — | WO | disclosed |
| US-20170152244-A1 | bis-Pyridazine Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-06-01 | — | — | US | disclosed |
| US-20170152254-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-06-01 | — | — | US | disclosed |
| US-20170152254-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-06-01 | — | — | US | disclosed |
| US-20170152244-A1 | bis-Pyridazine Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-06-01 | — | — | US | disclosed |
| CN-106795150-A | 1,3,4 thiadiazole compounds and its purposes in treating cancer | 阿斯利康(瑞典)有限公司 | 2017-05-31 | — | — | CN | disclosed |
| EP-3148994-A1 | 1, 3, 4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015181539-A1 | 1, 3, 4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2015-12-03 | — | — | WO | disclosed |
| WO-2015181539-A1 | 1, 3, 4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577354-B2 | Bis-pyridazine compounds and their use in treating cancer | GLS2, GLS, GLUL | PTGS1 433/4885KDM4E 700/4885L3MBTL1 1924/4885 |
| US-20190169172-A1 | bis-Pyridazine Compounds and Their Use in Treating Cancer | GLS2, GLS, GLUL | PTGS1 320/4885KDM4E 730/4885L3MBTL1 1719/4885 |
| US-20170152244-A1 | bis-Pyridazine Compounds and Their Use in Treating Cancer | GLS2, GLS, GLUL | PTGS1 433/4885KDM4E 700/4885L3MBTL1 1924/4885 |
| US-20170152254-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | GLS2, GLS, GLUL | PTGS1 287/4885KDM4E 455/4885L3MBTL1 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.